menu018.png

QUIMATRYX DEVELOPS AN EFFECTIVE EPIGENETIC DRUG AGAINST MANTLE CELL LYMPHOMA

QUIMATRYX has developed an epigenetic drug that has shown great efficacy in animal models against Mantle Cell Lymphoma.

https://lymphomanewstoday.com/2018/06/21/qtx125-slows-mantle-cell-lymphoma-progression-mouse-study/

Investor search in Quimatryx

Quimatryx has hired NORGESTION to search for one or more partners to rise €3 Million in two planned financial rounds between 2018 and 2019. This amount will be used to develop Quimatryx compound QTX125 (selective inhibitor against HDAC6) to clinical phase I for mantle cell lymphoma.

NEW GRANT FROM CDTI TO DEVELOP QTX125 HDAC6 SELECTIVE INHIBITOR

CDTI has approved a Neotec grant of 212.475€ to QUIMATRYX in support of the project “QUIMATRYX: DESARROLLO DE FÁRMACOS EPIGENÉTICOS”.

Thanks to this grant, Quimatryx will continue with the preclinical development of its most advanced HDAC6 inhibitor, QTX125, which is highly selective and active against this epigenetic target.

QTX125 has shown potent antitumoural activity in animal model against pancreatic cancer and, B-cell lymphomas. In addition, QTX125 has shown high efficacy in autoimmune disease animal models, such as multiple sclerosis.

Quimatryx at BIO-EUROPE 2016

Bio Europe

BIO-EUROPE 2016. November 7-9, 2016. Cologne, Germany. If you are also attending Bio-Europe and would like to meet us please fill our form to arrange an appointment.

 

   QUIMATRYX

   Paseo Mikeletegi 69, 3ª planta

   20009 San Sebastián

   Tel: 946 08 70 37

   www.quimatryx.com